CDKN2A and cancer: Several cancers show genetic/epigenetic inactivation of CDKN2A; they include melanoma, pancreatic, head and neck, skin, lung, esophageal, gastric, colorectal, ovarian, prostate, renal cell carcinoma, hepatic cancer, neuroblastoma, hematological cancer, and others [134,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169].